Positive News SentimentPositive NewsNASDAQ:BCTX BriaCell Therapeutics (BCTX) Stock Forecast, Price & News $5.56 +0.05 (+0.91%) (As of 09/26/2023 ET) Add Compare Share Share Today's Range$5.42▼$5.6950-Day Range$5.42▼$7.5352-Week Range$4.23▼$8.10Volume28,202 shsAverage Volume87,745 shsMarket Capitalization$88.85 millionP/E RatioN/ADividend YieldN/APrice Target$25.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media BriaCell Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside349.6% Upside$25.00 Price TargetShort InterestBearish8.55% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.56) to ($1.40) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.91 out of 5 starsMedical Sector882nd out of 963 stocksPharmaceutical Preparations Industry417th out of 452 stocks 3.5 Analyst's Opinion Consensus RatingBriaCell Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $25.00, BriaCell Therapeutics has a forecasted upside of 349.6% from its current price of $5.56.Amount of Analyst CoverageBriaCell Therapeutics has received no research coverage in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted8.55% of the float of BriaCell Therapeutics has been sold short.Short Interest Ratio / Days to CoverBriaCell Therapeutics has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.Change versus previous monthShort interest in BriaCell Therapeutics has recently increased by 3.67%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldBriaCell Therapeutics does not currently pay a dividend.Dividend GrowthBriaCell Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BCTX. Previous Next 3.8 News and Social Media Coverage News SentimentBriaCell Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for BriaCell Therapeutics this week, compared to 0 articles on an average week.MarketBeat Follows1 people have added BriaCell Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BriaCell Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders22.20% of the stock of BriaCell Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 17.33% of the stock of BriaCell Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BriaCell Therapeutics are expected to grow in the coming year, from ($1.56) to ($1.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BriaCell Therapeutics is -2.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BriaCell Therapeutics is -2.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBriaCell Therapeutics has a P/B Ratio of 8.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About BriaCell Therapeutics (NASDAQ:BCTX) StockBriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.Read More BCTX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BCTX Stock News HeadlinesAugust 31, 2023 | finance.yahoo.comBriaCell Therapeutics Corp. Announces Closing of Plan of Arrangement Spinning Out BriaPro Therapeutics Corp. to Existing ShareholdersAugust 31, 2023 | finance.yahoo.comBriaCell Accepts Letter of Intent from Weill Cornell Medicine Outlining Plans to Initiate a Clinical Trial of Bria-IMT™ in High-Risk Early-Stage Triple Negative Breast CancerSeptember 27, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."August 28, 2023 | bizjournals.comBriaCell receives court approval to launch spinoff aimed at accelerating cancer drug developmentJuly 10, 2023 | finance.yahoo.comBCTX: Pivotal Study Protocol ClearedJune 28, 2023 | benzinga.comHC Wainwright & Co. Reiterates Buy on BriaCell Therapeutics, Maintains $25 Price TargetJune 27, 2023 | baystreet.caFive Top Companies Fighting for the Treatment of Metastatic Breast CancerJune 27, 2023 | finance.yahoo.comFDA Approves BriaCell’s Pivotal Registrational Study Design in Advanced Metastatic Breast CancerSeptember 27, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."May 25, 2023 | baystreet.caThere are Positive Developments in the Treatment of Metastatic Breast CancerMay 15, 2023 | baystreet.caFive Impressive Metastatic Cancer Treatment Stocks to Own TodayMay 15, 2023 | finance.yahoo.comBriaCell Announces $4 Million Strategic Investment and Clinical Alliance with Prevail Partners, LLC and Prevail InfoWorks, Inc.April 27, 2023 | finance.yahoo.comBCTX: Posters Galore at AACRApril 10, 2023 | finance.yahoo.comBriaCell Therapeutics (TSE:BCT) Is In A Good Position To Deliver On Growth PlansMarch 30, 2023 | seekingalpha.comBriaCell plans spin-out of some pre-clinical assets into new entityMarch 24, 2023 | finanznachrichten.deUSA News Group: Evolution of Oncology Treatments Giving New Hope to Those Diagnosed with Breast CancerMarch 14, 2023 | finance.yahoo.comA BriaCell Therapeutics Corp. (TSE:BCT) insider increased their holdings by 20% last yearMarch 9, 2023 | finance.yahoo.comBCTX: 82% Survival BenefitFebruary 28, 2023 | seekingalpha.comBCTX BriaCell Therapeutics Corp.January 20, 2023 | finance.yahoo.comLab Notes: Amicus founder gets national honor; Capstan and Code Bio land on list of companies to watchDecember 19, 2022 | finance.yahoo.comBCTX: Down in San AntoneDecember 1, 2022 | benzinga.comBriaCell's Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer PatientsNovember 10, 2022 | finance.yahoo.comBriaCell Reports Positive Breast Cancer Efficacy Data with Bria-IMT™ Immunotherapy Treatment at SITC Annual MeetingOctober 31, 2022 | finance.yahoo.comBCTX: Fiscal Year 2022 ResultsOctober 14, 2022 | finance.yahoo.comHere's Why We're Not Too Worried About BriaCell Therapeutics' (TSE:BCT) Cash Burn SituationOctober 12, 2022 | finance.yahoo.comBriaCell Announces New Clinical Trial Site to Bring Novel Cancer Treatments to Advanced Breast Cancer PatientsSeptember 9, 2022 | benzinga.comBriaCell Announces Presentation at the 2022...See More Headlines Receive BCTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BriaCell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BCTX Company Calendar Today9/27/2023Next Earnings (Estimated)10/26/2023Fiscal Year End7/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BCTX CUSIPN/A CIK1610820 Webwww.briacell.com Phone(604) 921-1810Fax604-921-1898Employees5Year FoundedN/APrice Target and Rating Average Stock Price Forecast$25.00 High Stock Price Forecast$25.00 Low Stock Price Forecast$25.00 Forecasted Upside/Downside+349.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-26,840,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-997.24% Return on Assets-92.84% Debt Debt-to-Equity RatioN/A Current Ratio21.33 Quick Ratio21.33 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.67 per share Price / Book8.30Miscellaneous Outstanding Shares15,980,000Free Float12,434,000Market Cap$88.85 million OptionableNot Optionable Beta1.24 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. William V. Williams M.D. (Age 67)CEO, Pres & Director Comp: $710.99kMr. Gadi Levin B.Com. (Age 50)C.A., CPA, M.B.A., MBA, CFO & Corp. Sec. Comp: $247.09kDr. Miguel A. Lopez-Lago (Age 54)Chief Scientific Officer Comp: $246.62kDr. Giuseppe Del Priore M.D. (Age 61)M.P.H., MPH, Chief Medical Officer Comp: $438.86kDr. Charles Louis Wiseman FACP (Age 77)M.D., Founder, Principal Research Advisor & Member of Scientific Advisory Board Key CompetitorsImmunomeNASDAQ:IMNMChimerixNASDAQ:CMRXNGM BiopharmaceuticalsNASDAQ:NGMAnnovis BioNYSE:ANVSGlycoMimeticsNASDAQ:GLYCView All CompetitorsInsiders & InstitutionsNatixisBought 90,250 shares on 8/11/2023Ownership: 0.565%Wasatch Advisors LPSold 3,990 shares on 8/8/2023Ownership: 3.830%Concord Wealth PartnersSold 2,500 shares on 8/8/2023Ownership: 0.096%Simplex Trading LLCBought 100 shares on 8/4/2023Ownership: 0.000%Bank of Montreal CanBought 34,629 shares on 8/2/2023Ownership: 0.217%View All Insider TransactionsView All Institutional Transactions BCTX Stock - Frequently Asked Questions Should I buy or sell BriaCell Therapeutics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BriaCell Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BCTX shares. View BCTX analyst ratings or view top-rated stocks. What is BriaCell Therapeutics' stock price forecast for 2023? 1 analysts have issued 1 year price objectives for BriaCell Therapeutics' stock. Their BCTX share price forecasts range from $25.00 to $25.00. On average, they predict the company's share price to reach $25.00 in the next year. This suggests a possible upside of 349.6% from the stock's current price. View analysts price targets for BCTX or view top-rated stocks among Wall Street analysts. How have BCTX shares performed in 2023? BriaCell Therapeutics' stock was trading at $4.37 on January 1st, 2023. Since then, BCTX stock has increased by 27.2% and is now trading at $5.56. View the best growth stocks for 2023 here. When is BriaCell Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023. View our BCTX earnings forecast. When did BriaCell Therapeutics IPO? (BCTX) raised $15 million in an initial public offering on Wednesday, February 24th 2021. The company issued 3,300,000 shares at $4.25-$5.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO. What is BriaCell Therapeutics' stock symbol? BriaCell Therapeutics trades on the NASDAQ under the ticker symbol "BCTX." Who are BriaCell Therapeutics' major shareholders? BriaCell Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Wasatch Advisors LP (3.83%), Natixis (0.56%), K.J. Harrison & Partners Inc (0.22%), Bank of Montreal Can (0.22%), Concord Wealth Partners (0.10%) and Simplex Trading LLC (0.00%). View institutional ownership trends. How do I buy shares of BriaCell Therapeutics? Shares of BCTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is BriaCell Therapeutics' stock price today? One share of BCTX stock can currently be purchased for approximately $5.56. How much money does BriaCell Therapeutics make? BriaCell Therapeutics (NASDAQ:BCTX) has a market capitalization of $88.85 million. The company earns $-26,840,000.00 in net income (profit) each year or ($2.17) on an earnings per share basis. How can I contact BriaCell Therapeutics? BriaCell Therapeutics' mailing address is 3RD FLOOR BELLEVUE CENTRE 235-15TH STR, WEST VANCOUVER A1, V7T 2X1. The official website for the company is www.briacell.com. The company can be reached via phone at (604) 921-1810, via email at investors@briacell.com, or via fax at 604-921-1898. This page (NASDAQ:BCTX) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BriaCell Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.